2023-08-07 09:29:42 ET
- Pharvaris press release ( NASDAQ: PHVS ): Q2 GAAP EPS of -$0.63.
- Cash and cash equivalents were €179 million as of June 30, 2023, compared to €162 million for December 31, 2022.
- Research and Development (R&D) Expenses. R&D expenses were €14.7 million for the quarter ended June 30, 2023, compared to €13.7 million for the quarter ended June 30, 2022.
- General and Administrative (G&A) Expenses. G&A expenses were €7.8 million for the quarter ended June 30, 2023, compared to €7.7 million for the quarter ended June 30, 2022.
For further details see:
Pharvaris GAAP EPS of -$0.63